P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

por Dimopoulos, M., Opat, S., D’Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Garcia-Sanz, R., McCarthy, H., Mulligan, S., Tedeschi, A., Castillo, J. J., Czyz, J., Fernandez De Larrea Rodriguez, C., Belada, D., Libby, E., Matous, J., Motta, M., Siddiqi, T., Tani, M., Trneny, M., Minnema, M., Buske, C., Leblond, V., Treon, S. P., Trotman, J., Chan, W. Y., Schneider, J., Allewelt, H., Cohen, A., Huang, J., Tam, C. S.
Publicado 2022